July 11, 2023 10:45 AM EDTUpdated 01:27 PM
R&D

ADC Ther­a­peu­tics paus­es Zyn­lon­ta tri­al en­roll­ment af­ter sev­en pa­tient deaths, five se­ri­ous safe­ty events

Lei Lei Wu

News Reporter

ADC Ther­a­peu­tics said Tues­day morn­ing that it was stop­ping en­roll­ment in a study of Zyn­lon­ta af­ter sev­en pa­tients with dif­fuse large …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times